$ISCO
International Stem Cell CORP

2024 Q4 Form 10-Q Financial Statement

#000095017024126268 Filed on November 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $2.179M
YoY Change 10.44%
Cost Of Revenue $974.0K
YoY Change 24.71%
Gross Profit $1.205M
YoY Change 1.09%
Gross Profit Margin 55.3%
Selling, General & Admin $1.108M
YoY Change -2.29%
% of Gross Profit 91.95%
Research & Development $187.0K
YoY Change 20.65%
% of Gross Profit 15.52%
Depreciation & Amortization $53.00K
YoY Change 12.77%
% of Gross Profit 4.4%
Operating Expenses $1.295M
YoY Change 0.47%
Operating Profit -$90.00K
YoY Change -7.22%
Interest Expense -$35.00K
YoY Change -202.94%
% of Operating Profit
Other Income/Expense, Net -$35.00K
YoY Change 2.94%
Pretax Income -$125.0K
YoY Change -4.58%
Income Tax
% Of Pretax Income
Net Earnings -$125.0K
YoY Change -4.58%
Net Earnings / Revenue -5.74%
Basic Earnings Per Share -$0.02
Diluted Earnings Per Share -$0.02
COMMON SHARES
Basic Shares Outstanding 8.004M 8.004M
Diluted Shares Outstanding 8.004M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.307M
YoY Change -8.6%
Cash & Equivalents $1.307M
Short-Term Investments
Other Short-Term Assets $10.00K
YoY Change -37.5%
Inventory $1.384M
Prepaid Expenses $109.0K
Receivables $680.0K
Other Receivables $0.00
Total Short-Term Assets $3.490M
YoY Change -4.59%
LONG-TERM ASSETS
Property, Plant & Equipment $290.0K
YoY Change 19.34%
Goodwill
YoY Change
Intangibles $814.0K
YoY Change -8.74%
Long-Term Investments
YoY Change
Other Assets $254.0K
YoY Change -20.63%
Total Long-Term Assets $1.690M
YoY Change -14.78%
TOTAL ASSETS
Total Short-Term Assets $3.490M
Total Long-Term Assets $1.690M
Total Assets $5.180M
YoY Change -8.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $321.0K
YoY Change 5.94%
Accrued Expenses $475.0K
YoY Change 7.47%
Deferred Revenue
YoY Change
Short-Term Debt $3.357M
YoY Change -1.96%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.718M
YoY Change 0.77%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $203.0K
YoY Change -60.81%
Total Long-Term Liabilities $203.0K
YoY Change -60.81%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.718M
Total Long-Term Liabilities $203.0K
Total Liabilities $4.921M
YoY Change -5.37%
SHAREHOLDERS EQUITY
Retained Earnings -$110.7M
YoY Change 0.64%
Common Stock $8.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.041M
YoY Change
Total Liabilities & Shareholders Equity $5.180M
YoY Change -8.17%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$125.0K
YoY Change -4.58%
Depreciation, Depletion And Amortization $53.00K
YoY Change 12.77%
Cash From Operating Activities $257.0K
YoY Change 314.52%
INVESTING ACTIVITIES
Capital Expenditures $40.00K
YoY Change 185.71%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$40.00K
YoY Change 185.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -200.0K
YoY Change
NET CHANGE
Cash From Operating Activities 257.0K
Cash From Investing Activities -40.00K
Cash From Financing Activities -200.0K
Net Change In Cash 17.00K
YoY Change -64.58%
FREE CASH FLOW
Cash From Operating Activities $257.0K
Capital Expenditures $40.00K
Free Cash Flow $217.0K
YoY Change 352.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001355790
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2024Q3 us-gaap Notes Payable Current Related Party Type Extensible Enumeration
NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#RelatedPartyMember
CY2023Q4 us-gaap Notes Payable Current Related Party Type Extensible Enumeration
NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#RelatedPartyMember
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
CY2024Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-51891
dei Entity Registrant Name
EntityRegistrantName
INTERNATIONAL STEM CELL CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-4494098
dei Entity Address Address Line1
EntityAddressAddressLine1
9745 Businesspark Ave
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92131
dei City Area Code
CityAreaCode
760
dei Local Phone Number
LocalPhoneNumber
940-6383
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8004389
CY2024Q3 us-gaap Cash
Cash
1307000
CY2023Q4 us-gaap Cash
Cash
1588000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
680000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
574000
CY2024Q3 us-gaap Inventory Net
InventoryNet
1384000
CY2023Q4 us-gaap Inventory Net
InventoryNet
1263000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
119000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
96000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
3490000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
3521000
CY2024Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
223000
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
266000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
290000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
215000
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
739000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
800000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
407000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
557000
CY2024Q3 isco Deposits And Other Assets
DepositsAndOtherAssets
31000
CY2023Q4 isco Deposits And Other Assets
DepositsAndOtherAssets
31000
CY2024Q3 us-gaap Assets
Assets
5180000
CY2023Q4 us-gaap Assets
Assets
5390000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
321000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
364000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
475000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
485000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
315000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
276000
CY2024Q3 isco Advances From Nonaffiliated Collaboration
AdvancesFromNonaffiliatedCollaboration
250000
CY2023Q4 isco Advances From Nonaffiliated Collaboration
AdvancesFromNonaffiliatedCollaboration
250000
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
3357000
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3457000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4718000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4832000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
203000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
445000
CY2024Q3 us-gaap Liabilities
Liabilities
4921000
CY2023Q4 us-gaap Liabilities
Liabilities
5277000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8004389
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8004389
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8004389
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8004389
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
8000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
106642000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
106276000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110696000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110476000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-4041000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-4187000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5180000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5390000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2179000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1973000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6639000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5900000
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
974000
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
781000
us-gaap Cost Of Revenue
CostOfRevenue
2774000
us-gaap Cost Of Revenue
CostOfRevenue
2318000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
816000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
832000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2609000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2550000
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
292000
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
302000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
928000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
926000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
187000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
155000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
447000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
345000
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
2269000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
2070000
us-gaap Costs And Expenses
CostsAndExpenses
6758000
us-gaap Costs And Expenses
CostsAndExpenses
6139000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-90000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-97000
us-gaap Operating Income Loss
OperatingIncomeLoss
-119000
us-gaap Operating Income Loss
OperatingIncomeLoss
-239000
CY2024Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
35000
CY2023Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
34000
us-gaap Interest Expense Debt
InterestExpenseDebt
106000
us-gaap Interest Expense Debt
InterestExpenseDebt
105000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8000
isco Employee Retention Credit
EmployeeRetentionCredit
663000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-35000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-34000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-101000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
566000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-125000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-131000
us-gaap Net Income Loss
NetIncomeLoss
-220000
us-gaap Net Income Loss
NetIncomeLoss
327000
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
155000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-125000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-131000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-220000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
172000
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8004389
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8004389
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8004389
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8004389
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8004389
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8004389
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8004389
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8004389
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-4187000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
137000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-214000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-4264000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
129000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
119000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-4016000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
100000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-125000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-4041000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-4520000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
108000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-34000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4446000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
108000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
492000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-3846000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
118000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-131000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-3859000
us-gaap Profit Loss
ProfitLoss
-220000
us-gaap Profit Loss
ProfitLoss
327000
us-gaap Share Based Compensation
ShareBasedCompensation
366000
us-gaap Share Based Compensation
ShareBasedCompensation
334000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
152000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
146000
isco Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
150000
isco Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
124000
isco Interest Expense On Related Party Note Payable
InterestExpenseOnRelatedPartyNotePayable
100000
isco Interest Expense On Related Party Note Payable
InterestExpenseOnRelatedPartyNotePayable
99000
isco Change In Inventory Reserve
ChangeInInventoryReserve
28000
isco Change In Inventory Reserve
ChangeInInventoryReserve
40000
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
2000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
106000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-103000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
106000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-25000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
23000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
176000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-43000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-19000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-10000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-66000
isco Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-203000
isco Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-169000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
87000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
768000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
165000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
80000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
3000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-168000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-80000
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
200000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-200000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-281000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
688000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1588000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
742000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1307000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1430000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1000
us-gaap Interest Paid Net
InterestPaidNet
7000
us-gaap Interest Paid Net
InterestPaidNet
5000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Significant estimates include patent life (remaining legal life versus remaining useful life), inventories carrying values, and the fair value of stock option grants using the Black-Scholes option valuation model. By their nature, estimates are subject to an inherent degree of uncertainty and actual results could differ from these estimates.</span></p>
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2024Q3 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P15Y
us-gaap Revenue Performance Obligation Description Of Payment Terms
RevenuePerformanceObligationDescriptionOfPaymentTerms
The Company's revenue consists primarily of sales of products from its two revenue-generating operating segments, the biomedical market (LCT) and anti-aging market (LSC). The anti-aging market sells products solely through the ecommerce channel. The biomedical market sells primary human cell research products with two product categories, cells and media, which are sold both domestically and internationally. The biomedical market also offers performance of quality control (QC) testing services. No revenue from services was earned during the three and nine months ended September 30, 2024 and 2023.
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2024Q3 isco Number Of Products Categories
NumberOfProductsCategories
2
isco Product Return Guarantee Period
ProductReturnGuaranteePeriod
P30D
CY2024Q3 isco Allowance For Sales Returns
AllowanceForSalesReturns
0
CY2023Q3 isco Allowance For Sales Returns
AllowanceForSalesReturns
0
isco Reduction In Research And Development Expenses
ReductionInResearchAndDevelopmentExpenses
94000
isco Reduction In Research And Development Expenses
ReductionInResearchAndDevelopmentExpenses
99000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-125000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-131000
us-gaap Net Income Loss
NetIncomeLoss
-220000
us-gaap Net Income Loss
NetIncomeLoss
327000
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
155000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-125000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-125000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-131000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-131000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-220000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-220000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
172000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
172000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8004389
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8004389
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8004389
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8004389
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8004389
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8004389
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8004389
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8004389
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.02
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.02
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.02
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.02
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.03
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.03
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.02
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.02
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20055742
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16528759
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19625318
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15057204
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Customer Concentrations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the three months ended September 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customer accounted for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">52</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">47</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of consolidated product sales, respectively, and approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">56</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">52</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, of biomedical product sales. As of September 30, 2024 and December 31, 2023, the same customer accounted for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">41</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">47</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of accounts receivable, net, respectively.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the three months ended September 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, no other single customer accounted for more than 10% of revenues in any segment. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">One</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> other customer accounted for more than 10% of accounts receivable, net as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customers individually accounted for more than 10% of accounts receivable, net and in the aggregate, accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of accounts receivable, net.</span></p>
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
630000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
526000
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
620000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
597000
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1108000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1145000
CY2024Q3 us-gaap Inventory Gross
InventoryGross
2358000
CY2023Q4 us-gaap Inventory Gross
InventoryGross
2268000
CY2024Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
751000
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
739000
CY2024Q3 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1607000
CY2023Q4 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1529000
CY2024Q3 us-gaap Inventory Net
InventoryNet
1384000
CY2023Q4 us-gaap Inventory Net
InventoryNet
1263000
CY2024Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
223000
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
266000
CY2024Q3 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1607000
CY2023Q4 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1529000
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
109000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
80000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
10000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
16000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
119000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
96000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2628000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2541000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2338000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2326000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
290000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
215000
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
33000
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
27000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
90000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
85000
CY2024Q3 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
76000
CY2023Q3 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
78000
us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
3000
CY2024Q3 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
1291000
CY2023Q4 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
1290000
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
627000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
565000
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
664000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
725000
CY2024Q3 us-gaap Indefinite Lived Trademarks
IndefiniteLivedTrademarks
75000
CY2023Q4 us-gaap Indefinite Lived Trademarks
IndefiniteLivedTrademarks
75000
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
739000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
800000
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
20000
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
20000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
62000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
61000
CY2024Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2023Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
2000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Dividends Preferred Stock
DividendsPreferredStock
0
us-gaap Preferred Stock Voting Rights
PreferredStockVotingRights
The holders of Series B, Series D, and Series G are entitled to one vote for each share of common stock into which it would convert.
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
118000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
366000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
334000
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
378000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y4M24D
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
37351888
CY2021Q4 isco Lease Costs Incurred Percentage
LeaseCostsIncurredPercentage
0.40
isco Number Of Operating Leases
NumberOfOperatingLeases
3
CY2021Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2026-12-31
CY2021Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
11000
CY2021Q4 isco Percentage Of Increase Rent Per Annum Over Lease Term
PercentageOfIncreaseRentPerAnnumOverLeaseTerm
0.035
CY2021Q4 isco Percentage Of Base Rent Abated
PercentageOfBaseRentAbated
0.50
CY2021Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2026-12-31
CY2021Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
4000
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
70000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
71000
us-gaap Operating Lease Cost
OperatingLeaseCost
210000
us-gaap Operating Lease Cost
OperatingLeaseCost
213000
CY2024Q3 isco Finance Leases
FinanceLeases
0
CY2023Q4 isco Finance Leases
FinanceLeases
0
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
88000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
360000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
119000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
567000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
49000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
518000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
315000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
203000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2179000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1973000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6639000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5900000
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
2269000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
2070000
us-gaap Costs And Expenses
CostsAndExpenses
6758000
us-gaap Costs And Expenses
CostsAndExpenses
6139000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-90000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-97000
us-gaap Operating Income Loss
OperatingIncomeLoss
-119000
us-gaap Operating Income Loss
OperatingIncomeLoss
-239000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-35000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-34000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-101000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
566000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-125000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-131000
us-gaap Net Income Loss
NetIncomeLoss
-220000
us-gaap Net Income Loss
NetIncomeLoss
327000
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 isco Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2024Q3 isco Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false

Files In Submission

Name View Source Status
0000950170-24-126268-index-headers.html Edgar Link pending
0000950170-24-126268-index.html Edgar Link pending
0000950170-24-126268.txt Edgar Link pending
0000950170-24-126268-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
isco-20240930.htm Edgar Link pending
isco-20240930.xsd Edgar Link pending
isco-ex31_1.htm Edgar Link pending
isco-ex31_2.htm Edgar Link pending
isco-ex32_1.htm Edgar Link pending
isco-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
isco-20240930_htm.xml Edgar Link completed
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable